Shandong Jincheng Pharmaceutical Group Co., Ltd (SHE:300233)
China flag China · Delayed Price · Currency is CNY
12.88
+0.23 (1.82%)
Jul 31, 2026, 3:05 PM CST

SHE:300233 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
66.9344.19196.78174.71273.37107.98
Depreciation & Amortization
321.52321.52319.26308.17255.77224.03
Other Amortization
3.163.163.513.493.019.46
Loss (Gain) From Sale of Assets
-2.95-2.95-1.452.16-1.53-1.02
Asset Writedown & Restructuring Costs
23.8623.8614.532.4921.3239.07
Loss (Gain) From Sale of Investments
-2.79-2.791.67-0.598.68-12.5
Provision & Write-off of Bad Debts
0.390.39-2.492.77-0.08-4.52
Other Operating Activities
112.1638.8342.4888.0350.9178.41
Change in Accounts Receivable
58.1758.17-28.11-124.9-314.2-89.1
Change in Inventory
101.37101.37-115.5932.08-202.78-133.37
Change in Accounts Payable
-263.48-263.48-137.11213.55127.52194.72
Change in Other Net Operating Assets
----16.4621.35-
Operating Cash Flow
415.71319.64296.59664.08255.63437.19
Operating Cash Flow Growth
68.54%7.77%-55.34%159.78%-41.53%-19.95%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-111.44-100.88-142.61-342.9-373.67-376.14
Sale of Property, Plant & Equipment
51.5123.7962.2924.866.485.67
Divestitures
-----0.96-
Investment in Securities
-68.34-68.34-4103.9129.1
Other Investing Activities
-109.93-10.520.01-1.956.429.84
Investing Cash Flow
-238.19-155.96-84.32-309.99-357.82-231.54

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-137.98239348.37475.97383.7
Long-Term Debt Repaid
--274.17-283.38-449.03-418.99-390.7
Net Debt Issued (Repaid)
-174.42-136.19-44.38-100.6656.98-7
Issuance of Common Stock
----56.94-
Repurchase of Common Stock
---55.01---80.01
Common Dividends Paid
-104.24-162.51-131.67-83.52-104.78-105.19
Other Financing Activities
0.37--12.71-59.13-5.310.54
Financing Cash Flow
-278.29-298.7-243.77-243.313.83-191.66

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-0.481.845.963.474.3-4.97
Net Cash Flow
-101.26-133.17-25.54114.24-94.079.01

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
304.27218.76153.97321.18-118.0461.04
Free Cash Flow Growth
125.92%42.08%-52.06%---77.70%
Free Cash Flow Margin
11.00%7.99%4.56%9.08%-3.37%1.94%
Free Cash Flow Per Share
0.830.590.410.83-0.310.16
Levered Free Cash Flow
363.88278.7716.57251.22115.339.67
Unlevered Free Cash Flow
369.77285.5328.12266.8132.0926.57

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
201.86195.64172.91155.47114.1151.12
Change in Working Capital
-106.57-106.57-277.6982.85-355.82-3.72